論文・技術情報追加のお知らせ

1. Real-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database.

薬剤誘発性MGDのリスクを特定

対象DB：FAERS

2. A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.

PPIsの長期使用で腫瘍リスク増。慎重な使用必要

対象DB：FAERS

3. Using multiple drug similarity networks to promote adverse drug event detection.

早期有害事象検出に新手法提案、効果向上

対象DB：FAERS

4. Gabapentinoids related psychiatric disorders: an analysis based on the FAERS database from 2004 to 2023.

ガバペンチノイド使用で精神障害リスク増加

対象DB：FAERS

5. Vertebral artery dissection in a patient with migraine treated with calcitonin gene-related peptide monoclonal antibody: a case report and FAERS database analysis.

CGRP抗体治療中の椎骨動脈解離を報告

対象DB：FAERS

6. Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.

FAERS解析で複数薬の凝固障害リスクを特定

対象DB：FAERS

7. Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis.

ADC治療に関連する眼毒性を確認

対象DB：FAERS

8. A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System.

ソラフェニブ治療で新規副作用を特定、安全対策が重要

対象DB：FAERS

9. Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System.

経口内分泌療法で心血管・代謝異常のリスクが判明

対象DB：FAERS

10. Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.

ニルマトレルビルの新たな副作用が報告され注意が必要

対象DB：FAERS

11. Drug-induced Spontaneous intramural hematoma of the gastrointestinal tract: A real-world pharmacovigilance analysis.

抗凝固薬などが稀に胃腸内血腫を誘発するため注意が必要

対象DB：FAERS

12. Real-world individual and comparative analysis of adverse event reporting for adalimumab and etanercept using public FDA adverse event reporting system data.

エタネルセプトは注射部位反応で重大事象が多く要注意

対象DB：FAERS

13. Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials.

イサツキシマブは治療効果が高く、安全性も管理可能と確認

対象DB：FAERS

14. A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).

サクビトリル/バルサルタンの使用で耳毒性リスク増加を確認

対象DB：FAERS

15. Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases.

DRESS症候群の原因薬と致死率を分析

対象DB：FAERS

16. Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System.

JAK阻害薬はRA患者で消化管穿孔リスク増加、監視強化が重要

対象DB：FAERS

17. Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004-2023).

薬剤誘発性網膜静脈閉塞(RVO)の高リスク薬25種を特定

対象DB：FAERS

18. Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System.

IDH阻害剤は可逆的副作用で安全性良好

対象DB：FAERS

19. Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database.

アデュカヌマブの安全性を調査し、神経系障害を含む新たな副作用を特定

対象DB：FAERS

20. Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA Adverse Event Reporting System database from 2013 to 2024.

ベダキリン併用時、レボフロキサシンはモキシフロキサシンより安全性が示唆される

対象DB：FAERS

21. Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study.

眼科用ステロイド薬で白内障や視覚障害リスク、早期にADR多発

対象DB：FAERS

22. A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system.

抗精神病薬などで悪性症候群リスク増、男性多発

対象DB：FAERS

23. Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database.

抗真菌薬使用で重篤な皮膚有害事象リスク増加

対象DB：FAERS

24. Major adverse events associated with lipid reduction in inclisiran:a pharmacovigilance research of the FAERS database.

インクリシランで脂質低下に伴う重大有害事象を調査

対象DB：FAERS

25. Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System.

大麻と薬剤併用で重篤な有害事象リスク増加

対象DB：CVAR,FAERS

26. Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports.

小児における大麻製品と薬剤の相互作用注意喚起

対象DB：CVAR,FAERS

27. Adverse events in patients with castration-resistant prostate cancer treated with ra-223: a retrospective pharmacovigilance study.

ラジウム-223で未報告の有害事象を確認

対象DB：FAERS

28. Metoprolol adverse events and literature analyses: case/non-case analyses using the FDA Adverse Event Reporting System (FAERS).

メトプロロールに予期せぬ重篤な有害事象を確認

対象DB：FAERS

29. Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database.

スガマデックスは重篤な有害事象リスクあり注意必要

対象DB：FAERS

30. Adverse reactions associated with SSRIs and PD-1/PD-L1 inhibitors: a disproportionality analysis of the FDA Adverse Event Reporting System.

PD-1/PD-L1阻害剤とSSRI併用で有害事象増加

対象DB：FAERS

31. Fulminant type 1 diabetes mellitus: a neglected but high-risk adverse event associated with immune checkpoint inhibitors.

ICI療法は劇症1型糖尿病と強く関連

対象DB：FAERS

32. Pharmacologically induced autoimmune encephalitis-disproportionality analysis utilizing FAERS database.

薬剤誘発性自己免疫性脳炎のリスクを特定

対象DB：FAERS

33. Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database.

カペシタビンで未報告の有害事象を特定

対象DB：FAERS

34. DDI-GPT: Explainable Prediction of Drug-Drug Interactions using Large Language Models enhanced with Knowledge Graphs.

DDI-GPTは薬物相互作用を高精度で予測可能

対象DB：FAERS

35. Increasing Trends in the Pancreatitis Risk With Tumor Necrosis Factor Inhibitor Use.

TNF阻害薬使用は膵炎リスク増加と関連

対象DB：FAERS